Submit site search
  • HEK293::TMEM192-3xHA RB1CC1-/-

    By on

    HEK293::TMEM192-3xHA RB1CC1-/- PubMed=37757899; Characteristics: Using CRISPR/Cas9 TMEM192 was C-terminally tagged on both alleles with a 3xHA epitope (from parent cell line). Knockout cell: Method=CRISPR/Cas9; 15574; RB1CC1. Transformant: NCBI_TaxID; 28285; Adenovirus 5. Derived from site: In situ; Fetal kidney; UBERON=UBERON_0002113. NCBI_TaxID=9606; ! Homo sapiens (Human) RRID:CVCL_C0I5 ! HEK293::TMEM192-3xHA Female Fetus Transformed cell line

  • HeLa::TMEM192-3xHA

    By on

    HeLa ::TMEM192-3xHA PubMed=37757899; Population: African American. Characteristics: Using CRISPR/Cas9 TMEM192 was C-terminally tagged on both alleles with a 3xHA epitope (from parent cell line). Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18). Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002. NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma NCBI_TaxID=9606; ! Homo sapiens (Human) RRID:CVCL_0030 ! HeLa Female 30Y6M Cancer cell line

  • HEK293::TMEM192-3xHA RB1CC1-/- mNEON-YIPF4

    By on

    HEK293::TMEM192-3xHA RB1CC1-/- mNEON-YIPF4 PubMed=37757899; Characteristics: Using CRISPR/Cas9 TMEM192 was C-terminally tagged on both alleles with a 3xHA epitope (from parent cell line). Characteristics: Using CRISPR/Cas9 YIPF4 was N-terminally tagged on both alleles with mNeonGreen (PubMed=37757899). Knockout cell: Method=CRISPR/Cas9; 15574; RB1CC1. Transfected with: UniProtKB; A0A1S4NYF2; mNeonGreen (derivative of Branchiostoma lanceolatum blFP-Y3). Transformant: NCBI_TaxID; 28285; Adenovirus 5. Derived from site: In situ; Fetal kidney; UBERON=UBERON_0002113. NCBI_TaxID=9606; ! Homo sapiens (Human) RRID:CVCL_D1KQ ! HEK293::TMEM192-3xHA RB1CC1-/- Female Fetus

  • Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms

    By on

    Zenodo archive contains post-sequence QC, taxonomic, and functional profiling data. Supplementary Code includes workflow and bioinformatic processing used in the manuscript. Raw sequences and metadata are on NCBI SRA under BioProject ID PRJNA834801.

  • Population fraction of Parkinson’s disease attributable to preventable risk factors

    By on

    R-based Posit project for replicating Parkinson's disease risk factor analysis. Includes data in 'input' folder, .Rproj file, renv lockfile, workflow scripts, and output scripts. Refer to README.md for more details.

  • Microbial amyloids in neurodegenerative amyloid diseases

    By on

    Published: Inhibiting microbial amyloids or their interactions with the host, may therefore represent a tangible target to limit various amyloid pathologies.

  • Characterizing dysbiosis of the Parkinson’s disease gut microbiome using shotgun metagenomics

    By on

    Parkinson's disease is a progressive neurodegenerative condition with altered gut microbiome composition. A study analyzed fecal samples from 490 PD patients and 234 healthy individuals to understand dysbiosis at a detailed level.

  • Nigrostriatal Tau Pathology in parkinsonism and Parkinson’s disease

    By on

    While Parkinson’s disease remains clinically defined by cardinal motor symptoms resulting from nigrostriatal degeneration, it is now appreciated that the disease commonly consists of multiple pathologies, but it is unclear where these co-pathologies occur early in disease and whether they are responsible for the nigrostriatal degeneration. For the past number of years, we have been studying a well-characterized cohort of subjects with motor impairment that we have termed mild motor deficits. Motor deficits were determined on a modified and validated Unified Parkinson’s Disease Rating Scale III but were insufficient in degree to diagnose Parkinson’s disease. However, in our past studies, cases in this cohort had a selection bias, as both a clinical syndrome in between no motor deficits and Parkinson’s disease, plus nigral Lewy pathology as defined post-mortem, were required for inclusion. Therefore, in the current study, we only based inclusion on the presence of a clinical phenotype with mild motor impairment insufficient to diagnose Parkinson’s disease. Then, we divided this group further based upon whether or not subjects had a synucleinopathy in the nigrostriatal system. Here we demonstrate that loss of nigral dopaminergic neurons, loss of putamenal dopaminergic innervation and loss of the tyrosine hydroxylase-phenotype in the substantia nigra and putamen occur equally in mild motor deficit groups with and without nigral alpha-synuclein aggregates. Indeed, the common feature of these two groups is that both have similar degrees of AT8 positive phosphorylated tau, a pathology not seen in the nigrostriatal system of age-matched controls. These findings were confirmed with early (tau Ser208 phosphorylation) and late (tau Ser396/ Ser404 phosphorylation) tau markers. This suggests that the initiation of nigrostriatal dopaminergic neurodegeneration occurs independently of alpha-synuclein aggregation and can be tau mediated.

  • Peripheral MC1R Activation Modulates Immune Responses and is Neuroprotective in a Mouse Model of Parkinson’s Disease

    By on

    Preprint: The present study investigates the impact of NDP-MSH, a synthetic melanocortin receptor (MCR) agonist that does not cross BBB, on the immune system and the nigrostriatal dopaminergic system in mouse model of PD.

  • Peripheral MC1R activation modulates immune responses and confers neuroprotection in a mouse model of Parkinson’s disease

    By on

    Dataset corresponding to the article, "Peripheral MC1R activation modulates immune responses and confers neuroprotection in a mouse model of Parkinson's disease."

  • Fast-scan cyclic voltammetry to assess dopamine release in ex vivo mouse brain slices

    By on

    This protocol is to assess whether a drug changes the dopamine concentration released following a single pulse (1p) electrical stimulation.

  • Rethinking the network determinants of motor disability in Parkinson’s disease

    By on

    For roughly the last 30 years, the notion that striatal dopamine (DA) depletion was the critical determinant of network pathophysiology underlying the motor symptoms of Parkinson’s disease (PD) has dominated the field. While the basal ganglia circuit model underpinning this hypothesis has been of great heuristic value, the hypothesis itself has never been directly tested. Moreover, studies in the last couple of decades have made it clear that the network model underlying this hypothesis fails to incorporate key features of the basal ganglia, including the fact that DA acts throughout the basal ganglia, not just in the striatum. Underscoring this point, recent work using a progressive mouse model of PD has shown that striatal DA depletion alone is not sufficient to induce parkinsonism and that restoration of extra-striatal DA signaling attenuates parkinsonian motor deficits once they appear. Given the broad array of discoveries in the field, it is time for a new model of the network determinants of motor disability in PD.

  • A leaky gut dysregulates gene networks in the brain associated with immune activation, oxidative stress, and myelination in a mouse model of colitis

    By on

    The gut and brain are interconnected in human disease. Colitis models show reproducible genetic programs affecting both colon and brain, highlighting immune activation and potential therapeutic targets in the gut-brain axis.

  • Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation

    By on

    Studies show nanoplastic pollution can trigger α-synuclein protein fibrils formation and spread in the brain, potentially linking nanoplastics to Parkinson's disease and related dementias.

  • The R1441C-LRRK2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner

    By on

    Aging is a neglected factor in neurodegeneration research. LRRK2 gene variations impact PD risk.R1441C mutation boosts immune response in young, but leads to immune exhaustion with age.Understanding LRRK2's immune effects is crucial for PD treatment.

  • Central and peripheral innate and adaptive immunity in Parkinson’s disease

    By on

    Parkinson’s disease is a chronic inflammatory disorder affecting multiple systems. Innovative immunomodulatory interventions are needed to address central and peripheral immune responses during disease onset and progression.

  • Calcium influx into astrocytes plays a pivotal role in inflammation-driven behaviors

    By on

    Systemic inflammation can lead to astrogliosis, affecting neuronal activity linked to depressive behaviors. Orai1 calcium channel is crucial in this.Deleting Orai1 in astrocytes prevents astrogliosis, preserving normal neuronal activity and behavior.

  • CryoEM structure of amplified alpha-synuclein fibril class A type I with compact core from DLB case III

    By on

    Protein fibril classification for Homo sapiens expressed in Escherichia coli 'BL21-Gold(DE3)pLysS AG without mutations.

  • CryoEM structures of amplified alpha-synuclein fibril class A type I with extended core from DLB case I

    By on

    Protein fibril classification for Homo sapiens expressed in Escherichia coli BL21(DE3) without mutations.

  • CryoEM structure of amplified alpha-synuclein fibril class A type I with extended core from DLB case X

    By on

    Protein fibril classification for Homo sapiens, expressed in Escherichia coli strain BL21-Gold(DE3)pLysS AG without mutations.

Load More
Aligning Science Across Parkinson's
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.